4:07 PM
Mar 08, 2018
 |  BioCentury  |  Finance

CAR T confidence

How China’s JW leveraged growing enthusiasm for CAR T to raise $90M series A

The first CAR T therapy approvals in the U.S. followed by CFDA guidelines on cell therapy development and manufacturing gave a boost to Chinese investor interest in the space, enabling JW Therapeutics (Shanghai) Co. Ltd. to raise a $90 million series A round.

Temasek, Sequoia Capital China and YuanMing Capital led the round, which closed on March 7. Fellow new investors Oriza Seed Capital, Yipu Capital, AVICT Global Holdings, Shiyu Capital and LVC Capital Fund also participated, as did existing investors WuXi AppTec Co. Ltd. and Juno Therapeutics Inc., which Celgene Corp. (NASDAQ:CELG) acquired.

Read the full 450 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >